Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Catalent announced organizational changes within its biologics business.
read more
Wednesday, January 29, 2020
Catalent announced the appointment of Ricci Whitlow as President, Clinical Supply Services.
read more
Catalent, Inc. announced changes to its operating structure and executive leadership team that went into effect July 1. This new organizational structure includes a shift from four reporting segments to two, each representing roughly half of the ...
read more
Catalent announced it is investing up to $40 million at its manufacturing facility in Winchester, Kentucky.
read more
Thursday, October 03, 2019
Catalent announced Guy J. Dewil, M.D. has been appointed General Manager of its clinical supply facility in Schorndorf, Germany.
read more
Monday, February 22, 2021
Catalent recently signed a multi-year commercial supply agreement with Aurinia for LUPKYNIS, a drug to treat adult patients with lupus nephritis.
read more
Thursday, November 15, 2012
Catalent Pharma Solutions today announced that it had reached a commercial cell line sales agreement with CEVEC Pharmaceuticals for recombinant human alpha-1 antitrypsin (hAAT).
read more
Thursday, September 12, 2019
Catalent has announced professor David Schaffer has been appointed to the advisory board of the company’s biologics business.
read more
Monday, November 25, 2019
Catalent has appointed Mike Grippo as Senior Vice President, Strategy and Corporate Development.
read more
Catalent will provide support for the development, manufacturing, and clinical supply of Editas Medicine’s current and future portfolio of in vivo CRISPR medicines and engineered cell medicines.
read more
Catalent and Stirling Ultracold have announced a partnership whereby Stirling Ultracold becomes the preferred provider of ULT storage across Catalent’s multiple business units.
read more
Friday, December 05, 2014
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it had reached an exclusive development and licensing agreement...
read more
Wednesday, August 27, 2014
Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it is collaborating with privately held Australian biomarker research company, ...
read more
Wednesday, March 15, 2023
Catalent and Grünenthal announced their successful formulation design and clinical-phase manufacturing collaboration for an orally dosed small molecule in Grünenthal's pipeline.
Positive preclinical results from the molecule have allowed Grünenthal ...
read more
Thursday, January 12, 2023
Catalent and Ethicann Pharmaceuticals Inc. announced that the companies have executed a development and license agreement to develop Ethicann’s clinical drug pipeline using Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology.
read more